MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels

Neurobiology of Aging

Volumn 25, Issue 9, 2004, Pages 1169-1173

  Fenoglio, Chiara ^a   Galimberti, Daniela ^a   Lovati, Carlo ^b   Guidi, Ilaria ^a   Gatti, Alberto ^a   Fogliarino, Sergio ^c   Tiriticco, Marco ^a   Mariani, Claudio ^b   Forloni, Gianluigi ^c   Pettenati, Carla ^d   Baron, Pierluigi ^a   Conti, Giancarlo ^a   Bresolin, Nereo ^a   Scarpini, Elio ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d RHO HOSPITAL   (Italy)

Author keywords

Alzheimer's disease; Chemokines; Genetics; MCP 1; Monocyte chemoattractant protein 1; Polymorphism

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

AGE OF ONSET; AGED; ALZHEIMER DISEASE; CHEMOKINE CCL2; CHEMOKINES; CHEMOTAXIS, LEUKOCYTE; DNA MUTATIONAL ANALYSIS; ENCEPHALITIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HUMANS; ITALY; MALE; MUTATION; POLYMORPHISM, GENETIC; RISK FACTORS; SEX FACTORS; UP-REGULATION;

EID: 4143075666     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2003.11.008     Document Type: Article

References (17)

1. Del Bo R., Comi G.P., Bresolin N., Castelli E., Conti E., Degiuli A., et al. The apolipoprotein Eε4 allele causes a faster decline of cognitive performances in Down's syndrome subjects. J. Neurol. Sci. 145:1997;87-91
2. Galimberti D., Schoonenboom N., Scarpini E., Scheltens P. On behalf of the DIAR Group. Chemokines in serum and CSF of Alzheimer's disease patients. Ann. Neurol. 53:2003;547-548
3. Gonzalez E., Rovin B.H., Sen L., Cooke G., Dhanda R., Mummidi S. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. PNAS. 99:2002;13795-13800
4. Gunn M.D., Nelken N.A., Liao X., Williams L.T. Monocyte chemoattractant protein-1 is sufficient for the chemotaxis of monocytes and lymphocytes in transgenic mice but requires an additional stimulus for inflammatory activation. J. Immunol. 158:1997;376-383
5. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261:1993;921-923
6. Hizawa N., Yamaguchi E., Furuya K., Jinushi E., Ito A., Kawakami Y. The role of the CC chemokine receptor 2 gene polymorphism V64I (CCR2-64I) in sarcoidosis in a Japanese population. Am. J. Respir. Crit. Care Med. 159:1999;2021-2023
7. Inadera H., Egashira K., Takemoto M., Ouchi Y., Matsushima K. Increase in circulating levels of monocyte chemoattractant protein-1 with aging. J. Interferon Cytokine Res. 19:1999;1179-1182
8. Ishizuka K., Kimura T., Igata-yi R Katsuragi S., Takamatsu J., Miyakawa T. Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease. Psychiatry Clin. Neurosci. 51:1997;135-138
9. Kelder W., McArthur J.C., Nance-Sproson T., McClernon D., Griffin D.E. β-Chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann. Neurol. 44:1998;831-835
10. Lu B., Rutledge B.J., Gu L., Fiorillo J., Lukacs N.W. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J. Exp. Med. 187:1998;601-608
11. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338:1998;436-445
12. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 34:1984;939-944
13. Rovin H.R., Lu L., Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. BBRC. 259:1999;344-348
14. Sun Y.X., Minthon L., Wallmark A., Warkentin S., Blennow K., Janciauskiene S. Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 16:2003;136-144
15. Szalai C., Duba J., Prohàszka Z., Kalina A., Szabò T., Nagy B. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis. 158:2001;233-239
16. Ueda A., Ishigatzubo Y., Okubo T., Yoshimura T. Transcriptional regulation of the human monocyte chemoattractant protein-1 gene. Cooperation of the two NF-kappaB sites and NF-kappaB/Rel subunit specificity. J. Biol. Chem. 272:1997;31092-31099
17. Xia M.Q., Hyman B.T. Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J. Neurovirol. 5:1999;32-41